dabigatran has been researched along with Patent Foramen Ovale in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, D; Chen, S; He, J; Huang, P; Lai, Y; Sun, H; Wu, Q; Zhou, L | 1 |
| Chutinet, A; Diener, HC; Easton, JD; Granger, CB; Kleine, E; Marquardt, L; Meyerhoff, J; Sacco, RL; Zini, A | 1 |
2 trial(s) available for dabigatran and Patent Foramen Ovale
| Article | Year |
|---|---|
Dabigatran versus aspirin for stroke prevention after cryptogenic stroke with patent foramen ovale: A prospective study.
Topics: Aspirin; Dabigatran; Foramen Ovale, Patent; Humans; Ischemic Stroke; Prospective Studies; Recurrence; Risk Factors; Secondary Prevention; Stroke | 2022 |
Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale: Results From RE-SPECT ESUS.
Topics: Adolescent; Adult; Anticoagulants; Aspirin; Dabigatran; Double-Blind Method; Embolic Stroke; Embolism; Female; Foramen Ovale, Patent; Humans; Ischemic Stroke; Male; Middle Aged; Platelet Aggregation Inhibitors; Secondary Prevention; Young Adult | 2021 |